CircuLex 14-3-3γ ELISA Kit
14-3-3γ ELISA kit for quantitative measurement in CSF, cell lysates.
The 14-3-3 proteins are cerebrospinal fluid (CSF) biomarkers of neuronal damage for infectious agents and other neurological disorders. Specifically, the gamma-isoform of the 14-3-3 protein is expressed in neurons and can be an indicator for neuronal damage in prion disease. Creutzfeldt–Jakob disease (CJD) is a prion disease leading to degenerative brain disorder manifesting as dementia and, in due course, death. Creutzfeldt-Jakob disease (CJD) is diagnosed based on symptoms as well as neuroimaging biomarkers, neurophysiological tests, and CSF biomarkers (14-3-3). An elevated risk for CJD is associated with 14-3-3 levels above 100,000 AU/mL and a probable diagnosis of CJD based on laboratory parameters above 50,000 AU/mL. Hence, 14-3-3 γ ELISA is the best biomarker for prion disease according to its sensitivity and specificity compared to western blots.
In addition to CJD diagnosis, 14-3-3 proteins were demonstrated in neuroaxonal of patients with COVID-19. A correlation of CSF 14-3-3 levels was observed in patients that progress to a long-standing neuro-COVID disease. Consequently, further studies of 14-3-3 levels are warranted as a prognostic biomarker for neuronal damage during early to late phases of COVID-19 infection.
MBLI offers a quantitative measurement of 14-3-3 Gamma (gamma isoform protein) in CSF, cell lysates in 14-3-3 Gamma ELISA Kit.
The CycLex Research Product CircuLex 14-3-3 Gamma ELISA Kit is used for the quantitative measurement of 14-3-3γ (gamma isoform protein) in CSF (Cerebrospinal fluid), cell lysates and other biological samples in units of concentration. It can be used for 96 Assays.
|Product Type:||ELISA Kit|
|Research Area / Disease:||Cancer, Cell Biology|
|Sensitivity:||better than 250 AU/mL of sample.|
|Measurement Range:||Dilution factors need to be taken into consideration in calculating the units of 14-3-3 Gamma concentration. Results exceeding 14-3-3 Gamma level of 16,000 AU /mL should be repeated with diluted samples.|
|Regulatory Statement:||For Research Use Only. Not for use in diagnostic procedures.|
- 10X Wash Buffer
- Sample/Standard Dilution Buffer
- 14-3-3 Gamma Standard
- 00X 14-3-3 Gamma Detection Antibody
- Detection Antibody Dilution Buffer
- HRP conjugated Anti-IgG Antibody
- Conjugate Dilution Buffer
- Substrate Reagent
- Stop Solution
- Satoh, K, Nakamura, T. Human prion disease. Clin Exp Neuroimmunol. (2022) 13: 24– 33. doi:1111/cen3.12683
- Matthias Schmitz, Anna Villar-Piqué. et al. Diagnostic accuracy of cerebrospinal fluid biomarkers in genetic prion diseases. Brain. (2022) 145:2:700–712.10. doi:1093/brain/awab35
- Guasp M, Muñoz-Sánchez G et al. Neuro-COVID Study Group. CSF Biomarkers in COVID-19 Associated Encephalopathy and Encephalitis Predict Long-Term Outcome. Front Immunol. (2022) 13 866153. doi:0.3389/fimmu.2022.866153
- Falgàs, N, Ruiz-Peris, M, Pérez-Millan, A, et al. Contribution of CSF biomarkers to early-onset Alzheimer’s disease and frontotemporal dementia neuroimaging signatures. Hum Brain Mapp. (2020) 41: 2004– 2013. doi:10.1002/hbm.24925
- bu-Rumeileh, S., Baiardi, S., Polischi, B. et al. Diagnostic value of surrogate CSF biomarkers for Creutzfeldt–Jakob disease in the era of RT-QuIC. J Neurol. (2019) 266: 3110. doi:1007/s00415-019-095370
- Humpel C, Benke T: Cerebrospinal Fluid Levels of 14-3-3 Gamma: What Does It Tell Us About Sporadic Creutzfeldt-Jakob Disease? Pharmacology (2017) 100:243-245. doi:1159/000479115
- High sensitivity of an ELISA kit for detection of the gamma-isoform of 14-3-3 proteins: usefulness in laboratory diagnosis of human prion disease. Matsui Y, Satoh K, Miyazaki T, Shirabe S, Atarashi R, Mutsukura K, Satoh A, Kataoka Y, Nishida N. (2011) BMC Neurol. 11: 120.
- The role of cerebrospinal fluid proteins as early diagnostic markers for sporadic Creutzfeldt-Jakob disease. Pennington C, Chohan G, Mackenzie J, Andrews M, Will R, Knight R, Green A. (2009)Neurosci Lett. 455(1):56-9. (Epub 2009 Mar 5.)
- Total tau protein in cerebrospinal fluid and diffusion-weighted MRI as an early diagnostic marker for Creutzfeldt-Jakob disease. Satoh K, Shirabe S, Tsujino A, Eguchi H, Motomura M, Honda H, Tomita I, Satoh A, Tsujihata M, Matsuo H, Nakagawa M, Eguchi K. (2007) Dement Geriatr Cogn Disord. 24(3):207-12. (Epub 2007 Aug 10.)
- CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Sanchez-Juan P, Green A, Ladogana A, Cuadrado-Corrales N, Sáanchez-Valle R, Mitrováa E, Stoeck K, Sklaviadis T, Kulczycki J, Hess K, Bodemer M, Slivarichová D, Saiz A, Calero M, Ingrosso L, Knight R, Janssens AC, van Duijn CM, Zerr I. (2006) Neurology. 67(4):637-43.
- Determination of 14-3-3 protein levels in cerebrospinal fluid from Creutzfeldt-Jakob patients by a highly sensitive capture assay. Peoc’h K, Schröder HC, Laplanche J, Ramljak S, Müller WE. (2001) Neurosci Lett. 301(3):167-70.
- An enzyme-linked immunosorbent assay to quantify 14-3-3 proteins in the cerebrospinal fluid of suspected Creutzfeldt-Jakob disease patients. Kenney K, Brechtel C, Takahashi H, Kurohara K, Anderson P, Gibbs CJ Jr. (2000) Ann Neurol. 48(3):395-8.
- Isoform pattern of 14-3-3 proteins in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Wiltfang J, Otto M, Baxter HC, Bodemer M, Steinacker P, Bahn E, Zerr I, Kornhuber J, Kretzschmar HA, Poser S, Rüther E, Aitken A. (1999) J Neurochem. 73(6): 2485-90.
- The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. Hsich G, Kenney K, Gibbs CJ, Lee KH, Harrington MG. (1996) N Engl J Med. 335(13):924-30.